Literature DB >> 30443171

NDRG1 Downregulates ATF3 and Inhibits Cisplatin-Induced Cytotoxicity in Lung Cancer A549 Cells.

Aolin Du1, Yufeng Jiang1, Chuifeng Fan1.   

Abstract

N-myc downstream regulated gene 1 (NDRG1) plays a variety of roles in human cancers. Our previous studies showed that NDRG1 expression is elevated in non-small cell lung cancer and contributes to cancer growth. However, its function in apoptosis and chemoresistance in malignant tumors, including lung cancer, is not yet fully understood. In this study, we investigated the roles of NDRG1 in chemoresistance to cisplatin in lung cancer cells. We found that overexpression of NDRG1 significantly reduced cisplatin-induced cytotoxicity in lung cancer A549 cells, while overexpression of activating transcription factor 3 (ATF3), a stress-inducible gene found to be associated with apoptosis in some human cancers, significantly promoted cytotoxicity (P < 0.05). Further investigation showed that overexpression of NDRG1 significantly downregulated ATF3 and P53 expression in A549 cells, while overexpression of ATF3 significantly upregulated P53 expression (P < 0.05). In addition, cisplatin significantly upregulated ATF3, phospho-P53(ser46), and cleaved caspase 3 expression in lung cancer cells, but overexpression of NDRG1 in the presence of cisplatin reduced the level of these proteins elevated by cisplatin (P < 0.05). While, overexpression of ATF3 significantly promoted the cytoxicity induced by cisplatin in 1299 cells (p<0.05) (Figure 4), but overexpression of NDRG1 didn't regulate the cytoxicity induced by cisplatin (p>0.05). These results indicate that NDRG1 may contribute to cisplatin-resistance in lung cancer, possibly due to its function in the regulation of ATF3 expression.

Entities:  

Keywords:  ATF3; NDRG1; cisplatin; lung cancer

Mesh:

Substances:

Year:  2018        PMID: 30443171      PMCID: PMC6216061          DOI: 10.7150/ijms.28055

Source DB:  PubMed          Journal:  Int J Med Sci        ISSN: 1449-1907            Impact factor:   3.738


Introduction

The functions of N-myc downstream regulated gene 1 (NDRG1) in malignant tumors remain controversial 1-6. It was identified as a metastasis suppressor in some cancers 4, 6, but other studies have found that it can promote cancer growth and metastasis 1, 3, 5. A few studies have also indicated its possible association with cell apoptosis, but the mechanism involved remains unknown 7-12. NDRG1 was also reported to be involved in the regulation of cancer cell cytotoxicity induced by some anticancer agents, but the functions reported were contradictory and the associated mechanism was not elucidated 7, 8, 10, 11. ATF3, a stress-inducible gene, was also reported to play important roles in the regulation of cell apoptosis in some cancers and was associated with chemosensitivity 13-16. A study by Bandyopadhyay et al. identified ATF3 as a downstream target of NDRG1 in prostate cancer cells 17. However, the roles of these two proteins, and their interaction in cisplatin-chemoresistance in lung cancer cells, remain unclear. In this study, we investigated the role of NDRG1 in the regulation of chemosensitivity to cisplatin in lung cancer, and the possible role of ATF3.

Materials and Methods

Cell culture, transfection and cisplatin treatment

Human bronchial epithelial (HBE) cells and lung carcinoma cell lines were cultured in RPMI 1640 tissue culture medium (Invitrogen, Carlsbad, CA, USA), containing 10% fetal calf serum (Invitrogen), 100 IU/mL penicillin (Sigma, St Louis, MO, USA), and 100 μg/mL streptomycin (Sigma) at 37°C in a humidified atmosphere (5% CO2, 95% air). The cells were cultured in a 24-well plate for 24 h before transient transfection. Cells were then transfected with Lipofectamine 3000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The cells were harvested 48 h after transfection to measure the protein levels. To examine the effect of cisplatin on cancer cells, the cells were treated by cisplatin (50μM) for 24 h.

Western blotting

Cells were lysed in 10 volumes (w/v) of lysis buffer. After centrifugation, the supernatants were collected and quantified. The same amount of total protein was separated by 10% SDS-PAGE and then transferred to PVDF membranes. The membranes were then incubated overnight at 4°C with rabbit anti-human NDRG1 polyclonal antibody (ab63989, Abcam, HK; dilution 1:500), mouse anti-human ATF3 monoclonal antibody (sc-81189, Santa Cruz, USA; dilution 1:200), phospho-P53(ser46) antibody (2521, Millipore, CA; 1:500), P53 antibody (9282, Millipore, CA; 1:500), cleaved caspase 3 antibody (9664, Millipore, CA; 1:500), and mouse anti-human β-actin polyclonal antibody (ab20272, Abcam, HK; 1:500). After incubation with appropriate secondary antibodies labelled with HRP at room temperature for 2 h, protein bands were visualized using enhanced chemiluminescence (ECL) and detected using a BioImaging System.

Immunofluorescent staining

Cells were fixed with 4% paraformaldehyde and then blocked with 1% BSA, followed by incubation with rabbit anti-human NDRG1 polyclonal antibody (ab63989, Abcam, HK; dilution 1:100) and mouse anti-human ATF3 monoclonal antibody (sc-81189, Santa Cruz, USA; dilution 1:100) overnight at 4°C. The cells were then incubated with secondary antibodies conjugated to rhodamine/fluorescein isothiocyanate (FITC). The nuclei were counterstained with DAPI and the cells were examined with an Olympus IX51 fluorescence microscope (Olympus, Tokyo, Japan). Images were captured with a CoolPIX 5400 camera (Nikon, Japan).

Cell apoptosis and necrosis detection

Cell apoptosis and necrosis detection was performed with an AnnexinV-FITC/propidium iodide (PI) apoptosis detection kit (KeyGEN BioTECH Corp., Ltd, Jiangsu, China) according to the manufacturer's instructions. Cells were harvested using 0.25% trypsin 48 h after transfection and Annexin V/FITC and PI were added after washing twice with chilled PBS and resuspension in 250 μl of binding buffer. The cells were analyzed by FACSCalibur flow cytometer (Becton Dickinson, USA) after incubation for 30 min. Cells negative for both Annexin V and PI were considered viable. Cells showing Annexin V+/PI- were indicative of early apoptosis. Cells showing Annexin V+/PI+ were indicative of late apoptosis and necrosis.

Statistical analysis

SPSS statistical software package version 13.0 (SPSS Inc., Chicago, IL, USA) was used for the analyses. All data were expressed as means ± standard deviation (SD) of at least 3 in vitro experiments. Statistical significance was tested using an independent-samples t-test to compare data between two groups. P-values of <0.05 were considered statistically significant.

Results

NDRG1 and ATF3 show opposing effects on cisplatin-induced cytotoxicity in lung cancer cells

First, we examined NDRG1 and ATF3 expression using western blot and immunofluorescent staining in lung and lung cancer cell lines (Figure 1A). We selected A549 and H1299 cells to investigate the function of NDRG1 and ATF3 in vitro. Moderate levels of NDRG1 and ATF3 expression were observed in A549 cells and NDRG1 and ATF3 expression in H1299 cells was very low (Figure 1A). Immunofluorescent staining shows that ATF3 was located in cytoplasm and nuclear in both A549 and 1299 cells, while NDRG1 was located in cytoplasm and nuclear in 1299 cells, and mainly in cytoplasm with weak expression in nuclear in A549 cells (Figure 1B). Overexpression of NDRG1 and ATF3 in cancer cells by transfection of specific plasmids was confirmed by western blot (Figure 2). We examined cisplatin-induced cytotoxicity (cell apoptosis and necrosis) of lung cancer cells using Annexin V/PI double staining. Overexpression of NDRG1 significantly reduced the cytotoxicity to lung cancer A549 cells induced by cisplatin, while overexpression of ATF3 significantly promoted cytotoxicity (p<0.05) (Figure 3). While, overexpression of ATF3 significantly promoted the cytoxicity induced by cisplatin in 1299 cells (p<0.05) (Figure 4), but overexpression of NDRG1 didn't show a significant impact on the cytoxicity induced by cisplatin (p>0.05) (Figure 4).
Figure 1

NDRG1 and ATF3 expression using Western blot and immunofluorescent staining in lung and lung cancer cell lines. A549 and H1299 cells were selected to investigate the function of NDRG1 and ATF3 in vitro. There was a medium level of NDRG1 and ATF3 expression in A549 cells but very weak expression in 1299 cells (1A). ATF3 was located in cytoplasm and nuclear in both A549 and 1299 cells, while NDRG1 was located in cytoplasm and nuclear in 1299 cells, and mainly in cytoplasm with weak expression in nuclear in A549 cells (1B).

Figure 2

Overexpression of NDRG1 and ATF3 in A549 cancer cells (A) and H1299 cells (B) after transfection of specific plasmids was confirmed by western blot.

Figure 3

Flow cytometry analysis of cisplatin-induced cytotoxicity in A549 cells. Overexpression of NDRG1 significantly reduced the cytotoxicity to A549 lung cancer cells induced by cisplatin, while overexpression of ATF3 significantly promoted cytotoxicity (P < 0.05).

Figure 4

Flow cytometry analysis of cisplatin-induced cytotoxicity in H1299 cells. Overexpression of ATF3 significantly promoted the cytotoxicity induced by cisplatin in H1299 cells (p<0.05), while overexpression of NDRG1 didn't significantly impact on the cytotoxicity induced by cisplatin (p>0.05).

NDRG1 regulates cisplatin-induced expression of ATF3, phospho-P53 (ser46), and cleaved caspase 3 in lung cancer cells

We further examined the function of NDRG1 in the regulation of ATF3 expression. Overexpression of NDRG1 significantly downregulated ATF3 and P53 expression in A549 cells (p < 0.05) (Figure ). Overexpression of ATF3 significantly upregulated P53 expression (P < 0.05) but did not affect NDRG1 expression in A549 cells (P > 0.05) (Figure 5). While, in H1299 cells which has no P53 expression, overexpression of ATF3 didn't significantly regulate P53 and NDRG1 expression (p>0.05). These data indicate that the function of NDRG1 associated with chemoresistance is at least partly dependent on ATF3 in A549 cells. In H1299 cells, the function of ATF3 associated with chemoresistance is independent on P53. In addition, cisplatin significantly upregulated ATF3, phospho-P53(ser46), and cleaved caspase 3 expression in A549 cells, but overexpression of NDRG1 with addition of cisplatin reduced the elevated level of these proteins (Figure ) (P < 0.05). These results indicate that NDRG1 may contribute to chemoresistance to cisplatin by lung cancer cells through regulation of ATF3 and P53 in A549 cells.
Figure 5

Regulation of ATF3 and NDRG1 expression by NDRG1 overexpression. NDRG1 significantly downregulated ATF3 and P53 expression in A549 cells (*p < 0.05), but not in H1299 cells (p>0.05).

Discussion

NDRG1 is induced by hypoxia and cell differentiation signals 18. It has also been found to suppress tumor metastasis in some human cancers 4, 6. However, the role of NDRG1 in cancer cannot be generalized. There are also some studies show that it may play cancer-promoting roles, such as promotion of tumor growth and metastasis 1, 3, 5. According to these data, NDRG1 may have a variety of functions under different conditions and in different tumors. NDRG1 has also been linked to apoptosis and chemosensitivity in some malignant tumors 7-12. However, the mechanism involved was not fully elucidated. In this study, we found that overexpression of NDRG1 in lung cancer A549 cells significantly downregulated cisplatin-induced cytotoxicity. Our previous study showed that NDRG1 expression is elevated in non-small cell lung cancer and associated with cancer growth. Further studies have also shown that NDRG1 expression is increased in some other malignant tumors, such as malignant thyroid neoplasms 19 and hepatocellular carcinoma 20. Thus, it is important to understand the mechanism and function of NDRG1 in chemotherapy-induced cytotoxicity of cancer cells to improve chemosensitivity. ATF3 belongs to the ATF/cyclic AMP response element-binding (ATF/CREB) family 21. It has been found to play a variety of functions including regulation of metastasis, apoptosis, and proliferation in human cancers 21, 22. Bandyopadhyay et al. showed that ATF3 is a downstream target of NDRG1 in prostate cancer cells 17. Our study shows that NDRG1 can also downregulate ATF3 expression in lung cancer A549 cells. But the regulation of ATF3 by NDRG1 in H1299 cells was not significant, which may be because the expression level of ATF3 in H1299 cells was very low. Here we found that overexpression of ATF3 significantly upregulated cisplatin-induced cytotoxicity in both A549 and H1299 lung cancer cells. But overexpression of NDRG1 significantly downregulated chemosensitivity to cisplatin in lung cancer A549 cells, but not in H1299 cells. It may be because NDRG1 does not significantly regulate ATF3 in H1299 cells. Further we found that NDRG1 could inhibit the promotion of cisplatin-induced cytotoxicity by ATF3 in lung cancer cells. These results indicate that ATF3 may be involved in the mechanism of NDRG1 regulation of chemosensitivity to cisplatin in lung cancer, although further investigation is still needed to clarify the mechanism including how NDRG1 regulates ATF3 and how ATF3 regulates the apoptosis pathway induced by cisplatin.
  22 in total

1.  Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells.

Authors:  Eun Uk Jung; Jung-Hwan Yoon; Youn-Jae Lee; Jeong-Hoon Lee; Bo Hyun Kim; Su Jong Yu; Sun Jung Myung; Yoon Jun Kim; Hyo-Suk Lee
Journal:  Cancer Lett       Date:  2010-06-22       Impact factor: 8.679

2.  HIF-1α up-regulates NDRG1 expression through binding to NDRG1 promoter, leading to proliferation of lung cancer A549 cells.

Authors:  Qiang Wang; Li-Hong Li; Guo-Dong Gao; Gang Wang; Liang Qu; Jin-Ge Li; Chun-Mei Wang
Journal:  Mol Biol Rep       Date:  2013-03-25       Impact factor: 2.316

3.  NDRG1 protein overexpression in malignant thyroid neoplasms.

Authors:  Renê Gerhard; Suely Nonogaki; José Humberto Tavares Guerreiro Fregnani; Fernando Augusto Soares; Maria Aparecida Nagai
Journal:  Clinics (Sao Paulo)       Date:  2010-06       Impact factor: 2.365

4.  NDRG1 is necessary for p53-dependent apoptosis.

Authors:  Susanne Stein; Emily K Thomas; Birger Herzog; Matthew D Westfall; Jonathan V Rocheleau; Roger S Jackson; Mai Wang; Peng Liang
Journal:  J Biol Chem       Date:  2004-09-17       Impact factor: 5.157

Review 5.  NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states.

Authors:  Thomas P Ellen; Qingdong Ke; Ping Zhang; Max Costa
Journal:  Carcinogenesis       Date:  2007-10-04       Impact factor: 4.944

6.  NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis.

Authors:  Ying Zheng; Li-Shun Wang; Li Xia; Yu-Hui Han; Shi-Hua Liao; Xiao-Ling Wang; Jin-Ke Cheng; Guo-Qiang Chen
Journal:  Proteomics       Date:  2009-04       Impact factor: 3.984

7.  15,16-Dihydrotanshinone I-induced apoptosis in human colorectal cancer cells: involvement of ATF3.

Authors:  Fat-Moon Suk; Wen-Ju Jou; Ren-Jye Lin; Shyr-Yi Lin; Fang-Yu Tzeng; Yu-Chih Liang
Journal:  Anticancer Res       Date:  2013-08       Impact factor: 2.480

Review 8.  Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy.

Authors:  Bernard A Fang; Žaklina Kovačević; Kyung Chan Park; Danuta S Kalinowski; Patric J Jansson; Darius J R Lane; Sumit Sahni; Des R Richardson
Journal:  Biochim Biophys Acta       Date:  2013-11-21

Review 9.  The role of NDRG1 in the pathology and potential treatment of human cancers.

Authors:  Dong-Hun Bae; Patric J Jansson; Michael L Huang; Zaklina Kovacevic; Danuta Kalinowski; C Soon Lee; Sumit Sahni; Des R Richardson
Journal:  J Clin Pathol       Date:  2013-06-08       Impact factor: 3.411

10.  NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.

Authors:  Wen-Jing Lu; Mei-Sze Chua; Wei Wei; Samuel K So
Journal:  Oncotarget       Date:  2015-10-06
View more
  7 in total

1.  ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors.

Authors:  Ravyn M Duncan; Leticia Reyes; Katelyn Moats; Reeder M Robinson; Sara A Murphy; Balveen Kaur; Holly A F Stessman; Nathan G Dolloff
Journal:  Cancer Res       Date:  2020-06-19       Impact factor: 12.701

2.  Multifaceted and Intricate Oncogenic Mechanisms of NDRG1 in Head and Neck Cancer Depend on Its C-Terminal 3R-Motif.

Authors:  Guo-Rung You; Joseph T Chang; Hsiao-Fan Li; Ann-Joy Cheng
Journal:  Cells       Date:  2022-05-07       Impact factor: 7.666

3.  Estimation of Hub Genes and Infiltrating Immune Cells in Non-Smoking Females with Lung Adenocarcinoma by Integrated Bioinformatic Analysis.

Authors:  Jie Li; Ben Wang; Xin Li; Yuxi Zhu
Journal:  Med Sci Monit       Date:  2020-07-16

4.  RNA-Seq Analysis of Cisplatin and the Monofunctional Platinum(II) Complex, Phenanthriplatin, in A549 Non-Small Cell Lung Cancer and IMR90 Lung Fibroblast Cell Lines.

Authors:  Jerry D Monroe; Satya A Moolani; Elvin N Irihamye; Joshua S Speed; Yann Gibert; Michael E Smith
Journal:  Cells       Date:  2020-12-08       Impact factor: 6.600

5.  Ceramide induces the apoptosis of non‑small cell lung cancer cells through the Txnip/Trx1 complex.

Authors:  Yining Shi; Yongmei Jin; Fangfang Liu; Jianjun Jiang; Jiyu Cao; Youjin Lu; Jin Yang
Journal:  Int J Mol Med       Date:  2021-03-24       Impact factor: 4.101

6.  Down-Regulation of Activating Transcription Factor 3 (ATF3) in Hepatoblastoma and Its Relationship with Ferroptosis.

Authors:  Jing-Xiao Li; Jin-Shu Pang; Bin-Tong Yin; Gang Chen; Jun-Hong Chen; Jia-Yuan Luo; Xia Yang; Li-Ting Qin; Jiang-Hui Zeng; Peng Chen; Jia-Bo Chen; Deng Tang
Journal:  Int J Gen Med       Date:  2021-12-06

7.  Key genes and drug delivery systems to improve the efficiency of chemotherapy.

Authors:  Zally Torres-Martinez; Yamixa Delgado; Yancy Ferrer-Acosta; Ivette J Suarez-Arroyo; Freisa M Joaquín-Ovalle; Louis J Delinois; Kai Griebenow
Journal:  Cancer Drug Resist       Date:  2021-03-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.